Current Treatment Options in Oncology最新文献

{"title":"Breakthroughs in HBV-related HCC Therapy: The Unmatched Potential of Immune Checkpoint Inhibitors.","authors":"Chenlu Liu, Le Chang, Ying Yan, Huimin Ji, Jie Ma, Huizhen Sun, Lunan Wang","doi":"10.1007/s11864-026-01395-z","DOIUrl":"10.1007/s11864-026-01395-z","url":null,"abstract":"<p><strong>Opinion statement: </strong>Immune checkpoint inhibitors have reshaped the therapeutic landscape of hepatocellular carcinoma by restoring T cell-mediated antitumor immunity. However, the clinical benefit of monotherapy remains limited, highlighting the need for improved patient stratification and more effective treatment strategies. HBV-related hepatocellular carcinoma (HBV-HCC) is a major etiological subtype characterized by a chronically immunosuppressive tumor microenvironment driven by persistent viral antigen exposure and immune exhaustion. We believe that patients with HBV-HCC may be more suitable for immunotherapy, especially treatment with immune checkpoint inhibitors. A deeper understanding of the expression patterns of inhibitory checkpoint and costimulatory molecules, along with the identification of predictive biomarkers and the development of effective combination immunotherapies is essential for improving clinical outcomes. From a safety perspective, hepatitis B virus reactivation is generally manageable when appropriate antiviral therapy is administered concurrently with immunotherapy. Consequently, patients with HBV-HCC should not be excluded from treatment with immune checkpoint inhibitors. We anticipate that combination strategies, including multi-target immune checkpoint blockade, combinations with other immunotherapeutic approaches, and microbiome-based therapy, will further enhance therapeutic efficacy in HBV-HCC. Combination immune checkpoint therapy may enhance antitumor responses and potentially contribute to better control of viral activity.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148007390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.","authors":"Iraj Alipourfard, Zahra Shafaghat, Saber Saharkhiz, Marzieh Ramezani Farani, Salar Bakhtiyari","doi":"10.1007/s11864-025-01371-z","DOIUrl":"10.1007/s11864-025-01371-z","url":null,"abstract":"<p><p>Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment outcomes of patients with hematologic malignancies, including B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM). However, issues such as antigen escape, T-cell exhaustion, and the limited efficacy of CAR-T cells in acute myeloid leukemia (AML) and T-cell leukemias still persist. This review aims to summarize human trials and achievements from 2015 with a focus on the innovations within the last two years. We discuss strategies to overcome resistance, including multi-target CARs, next-generation constructs, and combination strategies to treat resistant cancers. We also explore the ways to increase safety and access, including allogeneic CAR-T options. In this article, we propose CRISPR-enhanced CARs and synthetic biology-based allogeneic systems to enhance the efficacy and accessibility of CAR-T therapy with the aim of moving the field of oncology towards durable cures.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13198482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148007316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemithorax Irradiation for High-Risk Chest Wall Sarcomas: Current Evidence, Clinical Practice and Future Directions.","authors":"YuanYou Yang, Xin Sun, Jie Xu, Lu Xie, Gang Ren","doi":"10.1007/s11864-026-01394-0","DOIUrl":"10.1007/s11864-026-01394-0","url":null,"abstract":"<p><strong>Opinion statement: </strong>Hemithorax irradiation (HT‑RT) is a cornerstone multimodal treatment for high‑risk chest wall bone and soft tissue sarcomas, particularly Ewing sarcoma in children and young adults. Current non‑randomized evidence consistently shows HT‑RT reduces systemic relapse-especially lung metastases-without compromising local control or causing unmanageable acute toxicities, and modern techniques (IMRT, VMAT, proton therapy) further improve its therapeutic ratio by lowering late toxicity. Major gaps remain: no prospective randomized controlled trials (RCTs) confirm independent efficacy, the biological mechanisms are unclear, and long‑term pulmonary function and survivorship data in children are insufficient. Future research must prioritize prospective RCTs, pediatric‑specific dose constraints, advanced technique validation, and mechanistic studies to refine patient selection and optimize outcomes for this high‑risk population.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13190504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147976798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Therapy for Solitary Fibrous Tumor.","authors":"Georgios M Stergiopoulos, Gabriel Tinoco, Steven I Robinson","doi":"10.1007/s11864-026-01383-3","DOIUrl":"10.1007/s11864-026-01383-3","url":null,"abstract":"<p><strong>Opinion statement: </strong>Solitary fibrous tumor (SFT) is an exceedingly rare mesenchymal neoplasm classified as a soft tissue sarcoma (STS). While historically considered indolent, up to 50% of cases can recur or metastasize after long-term follow-up. Complete surgical resection constitutes the cornerstone of treatment for localized disease, while the management of locally advanced or metastatic SFT poses a significant clinical challenge underscoring the need for effective systemic therapies. Antiangiogenic agents have shown promising outcomes, particularly in non-dedifferentiated SFT, and are increasingly favored by some as first-line options. Regarding chemotherapy, traditional anthracycline-based STS regimens have demonstrated limited efficacy, shifting the current focus towards combinations with alkylating agents, such as dacarbazine, and other agents such as microtubule inhibitors, like trabectedin. This review summarizes current systemic therapeutic strategies for SFT, highlighting the central role of antiangiogenic therapy as the standard backbone for managing advanced disease. It also discusses current data on chemotherapy, as well as molecularly targeted and immunomodulatory approaches, which are emerging options that require further validation. In addition, we discuss evolving concepts in systemic treatment sequencing, predictive biomarkers, advanced therapeutic combinations under clinical evaluation, and potential future therapeutic agents and targets.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13183738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147965266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing Unmet Needs in the Management of Small Cell Lung Cancer: Treatment of Brain Metastases, Quality of Life, and the Role of Real-World Evidence.","authors":"Yunfei Dai, Jing Fei","doi":"10.1007/s11864-026-01392-2","DOIUrl":"10.1007/s11864-026-01392-2","url":null,"abstract":"<p><strong>Opinion statement: </strong>Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor. Although patient survival has been significantly improved by immune checkpoint inhibitors combined with chemotherapy, three major unmet needs remain in SCLC management. First, while prophylactic cranial irradiation (PCI) can reduce the risk of brain metastases, its neurotoxicity limits its use, particularly in elderly patients or those with neurological deficits. Whole-brain radiotherapy (WBRT) remains the primary approach for brain metastases, and hippocampal-avoidance WBRT (HA-WBRT) combined with neuroprotective agents can significantly reduce cognitive risks. Stereotactic radiosurgery (SRS) has shown survival benefits and less cognitive damage for patients with up to 10 brain metastatic lesions. Emerging therapies, such as antibody-drug conjugates targeting B7-H3/DLL3 (I-Dxd, ZL-1310) and bispecific antibody tarlatamab, have demonstrated intracranial response rates of 62.5%-71%. Regardless of whether the brain metastases had previously undergone radiation therapy, the novel drugs showed consistent activity, indicating promising improvements in the prognosis of brain metastases. Second, the rapid progression and severe treatment-related toxicity of SCLC greatly affect patients' physical and mental well-being. Therefore, quality of life (QoL) should be prioritised. Strategies to improve QoL include early palliative care, proactive symptom management, application of HA-WBRT or SRS to preserve neurocognitive function, and novel agents such as tarlatamab to alleviate symptoms including cough and dyspnoea. Third, real-world evidence (RWE), which complements clinical trial data by reflecting treatment efficacy and safety in routine clinical practice, is gaining increasing recognition but faces challenges due to data heterogeneity, bias, and lack of methodological standardization. Future directions involve developing new drugs with high blood-brain barrier penetration, such as radioligand therapy, conducting prospective studies to optimize HA and SRS applications, establishing high-quality RWE databases to support personalized treatments, exploring molecular subtypes (SCLC-A/N/P/I) and leveraging AI technologies to advance precision radiotherapy. SCLC management needs to be patient-centered, integrating precise treatment of brain metastases, QoL improvement, and the application of RWE to achieve a balance between survival benefits and QoL.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13157436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging Strategies and Research Advances in Gastrointestinal Stromal Tumors.","authors":"Dongxiao Yang, Guanghui Yu","doi":"10.1007/s11864-026-01389-x","DOIUrl":"10.1007/s11864-026-01389-x","url":null,"abstract":"<p><p>OPINION STATEMENT: The therapeutic landscape of GIST has evolved considerably with the widespread use of tyrosine kinase inhibitors and improved molecular characterization. For localized disease, complete surgical resection remains the primary treatment strategy, while TKI therapy is indicated for unresectable, metastatic, or high-risk tumors and as adjuvant treatment in selected patients. In this setting, imaging is fundamental to treatment selection and longitudinal management. In our practice, contrast-enhanced CT is the first-line modality for initial staging and assessment of resectability. Imaging findings guide decisions regarding upfront surgery versus neoadjuvant TKI therapy, particularly in large or anatomically challenging tumors where downsizing may facilitate organ-preserving resection. During systemic therapy, we rely on CT for routine monitoring but recognize that size criteria alone may underestimate early response. We therefore integrate MRI or FDG PET/CT selectively when treatment response is unclear or early resistance is suspected. Postoperatively, surveillance strategies are tailored according to recurrence risk and adjuvant therapy status. High-risk patients undergo closer imaging follow-up, whereas surveillance intensity may be reduced in low-risk cases to limit cumulative radiation exposure. Ultimately, careful integration of imaging with clinical and molecular factors enables more individualized and stage-appropriate management of GIST.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147787727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Pharmacologic- and Non-pharmacologic Interventions for Cancer Pain: A Narrative Review.","authors":"Shulin Wang, Jingyu Yao, Qiuli Wang, Wei Yang, Jun Zhao","doi":"10.1007/s11864-026-01393-1","DOIUrl":"10.1007/s11864-026-01393-1","url":null,"abstract":"<p><p>OPINION STATEMENT: Cancer pain is common, heterogeneous, and multidimensional. The management of cancer pain is evolving toward a personalized, mechanism-informed, and multimodal paradigm. In my practice, systematic pain assessment is performed early, and individualized analgesic therapy is initiated promptly rather than deferred until tumor-directed therapy achieves measurable effects. Opioids remain essential but are limited by toxicity, tolerance, and incomplete control of mixed nociceptive-neuropathic mechanisms. Careful agent selection, dose titration, proactive management of constipation and neurotoxicity, and early consideration of opioid rotation are essential to sustain efficacy and safety. Evidence questions routine acetaminophen add-on to strong opioids and supports individualized risk stratification when using nonsteroidal anti-inflammatory drugs (NSAIDs). For neuropathic and treatment-related pain, gabapentinoids and duloxetine remain key adjuvants. Emerging options, including cannabinoids, novel gabapentinoids (mirogabalin and criligabalin), anti-nerve growth factor (NGF) antibodies, and transient receptor potential vanilloid 1 (TRPV1)-targeted therapies (intrathecal resiniferatoxin and high-concentration capsaicin patches), show variable efficacy and require further evaluation before routine use. For refractory pain, neurolytic blocks, intrathecal drug delivery, and neuromodulation may provide meaningful opioid-sparing analgesia in selected patients. These strategies can provide meaningful analgesia and reduce systemic opioid exposure. Nonpharmacologic modalities, including cognitive-behavioral therapy, mindfulness-based interventions, exercise, acupuncture, and transcutaneous electrical nerve stimulation, should be incorporated whenever feasible to reduce symptom burden, improve physical function, and support patient coping and overall well-being. This approach ensures that pharmacologic and nonpharmacologic strategies are applied in an integrated, patient-centered manner. Ultimately, optimal cancer pain management requires coordinated multidisciplinary care, shared decision-making, and ongoing reassessment to align analgesic strategies with disease trajectory, patient goals, and quality of life.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147787609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Current Cardio-Oncology Landscape Across Australia.","authors":"Daniel H Chen, Lloyd Butel-Simoes, Mitchum Bower, Mark T Nolan, Sanjeev S Kumar, Trent D Williams, Bogda Koczwara, Philippa Ell, Joshua D Bennetts, Gayathri R Nair, John Lee, Satish Ramkumar, Doan T M Ngo, Aaron L Sverdlov","doi":"10.1007/s11864-026-01390-4","DOIUrl":"10.1007/s11864-026-01390-4","url":null,"abstract":"<p><strong>Opinion statement: </strong>Cardio-oncology is a rapidly evolving subspecialty at the intersection of cancer and cardiovascular disease (CVD), two of Australia's leading causes of morbidity and mortality. Advances in cancer detection and therapy have markedly improved survival, resulting in a growing cohort of more than 1.2 million Australian cancer survivors. However, these patients are at increased risk of cardiovascular toxicity from cancer therapies, with CVD now surpassing recurrent malignancy as a leading cause of late mortality. In response, several quaternary and tertiary Australian public hospitals have established cardio-oncology services through grassroots initiatives, this has evolved into structured clinics embedded within tertiary hospitals. Despite increasing recognition and demand, access remains uneven, with services concentrated in metropolitan centres and limited provision for rural, remote, and Indigenous populations. National professional societies, including the Cardiac Society of Australia and New Zealand (CSANZ) and the Clinical Oncology Society of Australia (COSA), have recently established collaborative working groups to advance education, guidelines, and advocacy. Australia has also made significant research contributions through registries such as the Australian Cardio-Oncology Registry (ACOR) and clinical trials including SUCCOUR, BREXIT, and SMART-BREAST. Looking forward, key priorities for the Australian cardio-oncology community have surfaced including scaling workforce capacity, integrating structured education and training, expanding outreach and telehealth models, and addressing health inequities in underserved populations. These priorities along with upcoming initiatives such as the ACORES symposium will play an essential role in developing this sub speciality field. This review provides a comprehensive overview of the current cardio-oncology landscape across Australia, outlining its development, achievements, challenges, and future directions.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13091860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147718852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.","authors":"Bulent Cetin, Dilek Erdem, Irem Karaman, Ozge Gumusay","doi":"10.1007/s11864-026-01391-3","DOIUrl":"10.1007/s11864-026-01391-3","url":null,"abstract":"<p><p>OPINION STATEMENT: We focus our second-line treatment strategy on biomarker-defined resistance mechanisms that emerge after progression on CDK4/6 inhibitors. In our view, ESR1 mutation–mediated resistance constitutes a biologically distinct phenotype of endocrine resistance rather than a simple treatment escape. Therefore, in patients with ESR1-mutated tumors, we strongly favor incorporating next-generation oral selective estrogen receptor degraders (SERDs), given their targeted mechanism, favorable tolerability, and efficacy following CDK4/6 inhibition. For tumors harboring alterations in the PIK3CA–AKT–PTEN pathway, treatment selection is similarly biomarker driven. In patients with PIK3CA mutations, fulvestrant combined with alpelisib remains an effective option, though tolerability concerns often influence long-term adherence; accordingly, we increasingly prefer fulvestrant with capivasertib due to its activity across PIK3CA, AKT1, and PTEN alterations and its more manageable safety profile. When patients exhibit rapid progression, endocrine-independent biology, or aggressive visceral disease, we transition early to antibody–drug conjugates such as trastuzumab deruxtecan or sacituzumab govitecan, which demonstrate superior outcomes compared with conventional chemotherapy in appropriately selected cases. Overall, an individualized, biomarker-driven approach remains central to optimizing therapeutic sequencing in advanced HR+ breast cancer.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13091897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147718887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review on Photodynamic Therapy Combined with T-Cell Immunotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Mechanisms, Challenges, and Future Directions.","authors":"Wei Wang, Ping Liu, Haonan Lin","doi":"10.1007/s11864-026-01388-y","DOIUrl":"10.1007/s11864-026-01388-y","url":null,"abstract":"<p><p>OPINION STATEMENT: Nasopharyngeal carcinoma (NPC) exhibits a distinct geographical prevalence, with 75% of global cases concentrated in Southeast Asia and southern China. Clinically, its diagnosis and treatment are confronted with two core challenges: approximately 75% of patients are diagnosed at the locally advanced stage, and 20%-30% of patients eventually experience treatment failure due to disease recurrence or distant metastasis.​Despite the fact that modern medicine has developed conventional salvage treatment regimens for recurrent /metastatic Nasopharyngeal carcinoma(R/M NPC), including radiotherapy, chemotherapy, and surgery, these approaches still fail to achieve optimal disease control. This is primarily attributed to the biological characteristics of the tumor and limitations in therapeutic technologies, making the selection of treatment regimens a major clinical challenge.​In recent years, T-cell immunotherapy has emerged as a promising new direction for NPC treatment. However, it lacks support from large-scale phase III clinical trial data, and its efficacy stability and safety have not yet met clinical expectations. The advent of photodynamic therapy (PDT) has brought a new opportunity for NPC treatment. Although PDT has inherent drawbacks such as insufficient reactive oxygen species (ROS) production, uneven photosensitizer distribution, and low delivery efficiency, it can significantly enhance the anti-tumor activity of T cells, laying a solid foundation for combination therapy.​Therefore, this article will synthesize the available data to date and explore the potential of combining T-cell immunotherapy with PDT for the treatment of R/M NPC.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147629037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}